Showing results (201-210 of 221) with videos related to
Sort By:
Pageof 23
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialMace L Rothenberg, Amit M Oza, Robert H Bigelow, et al.Gynecologic Oncology|December 8, 2004
Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group studyMace L Rothenberg, P Y Liu, Sharon Wilczynski, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1996
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerM L Rothenberg, M J Moore, M C Cripps, et al.International Journal of Nanomedicine|February 25, 2015
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumorsHuali Wu, Jeffrey R Infante, Vicki L Keedy, et al.Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|February 14, 2008
TGF-beta signalling-related markers in cancer patients with bone metastasisJose Baselga, Mace L Rothenberg, Josep Tabernero, et al.The Oncologist|January 18, 2007
The continuum of care: a paradigm for the management of metastatic colorectal cancerRichard M Goldberg, Mace L Rothenberg, Eric Van Cutsem, et al.Cancer|March 26, 1999
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinomaM L Rothenberg, J V Cox, R F DeVore, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2023
Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized TrialH A Burris, M J Moore, J Andersen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialH A Burris, M J Moore, J Andersen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2009
Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumorsA Craig Lockhart, Mace L Rothenberg, Jakob Dupont, et al.Pageof 23